[go: up one dir, main page]

AR075032A1 - Pirazinonas sustituidas - Google Patents

Pirazinonas sustituidas

Info

Publication number
AR075032A1
AR075032A1 ARP100100118A ARP100100118A AR075032A1 AR 075032 A1 AR075032 A1 AR 075032A1 AR P100100118 A ARP100100118 A AR P100100118A AR P100100118 A ARP100100118 A AR P100100118A AR 075032 A1 AR075032 A1 AR 075032A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
or3b
halo
cyano
Prior art date
Application number
ARP100100118A
Other languages
English (en)
Inventor
John William Benbow
Jeffrey Allen Pfefferkorn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR075032A1 publication Critical patent/AR075032A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos que actuan como activadores de la glucocinasa, composiciones farmacéuticas de los mismos, y métodos para tratar enfermedades, trastornos o afecciones mediados por la glucocinasa. Reivindicacion 1: Compuesto caracterizado porque es de formula (1) en el que R1 es H, alquilo C1-3, o aIquilo C1-3 halosustituido; R2 es H o alquilo C1-3; R3 es heteroarilo de 5 o 6 átomos que contiene uno o dos heteroátomos de N, en el que dicho heteroarilo está opcionalmente sustituido con R3a, en el que R3a es alquilo C1-3, -CF3, ciano, alcoxi C1-3, halo, amino, alquilamino C1-3-, dialquilamino C1-3-, -C(O)OR3b, -alquil C1-3-C(O)OR3b, -C(O)NR3bR3c, o aril-alquil C1-3-, en el que R3b y R3c son cada uno independientemente H o alquilo C1-3, y en el que el arilo de dicho aril-alquilo C1-3 está opcionalmente sustituido con alquilo C1-3, -CF3, ciano, alcoxi C1-3, o halo; R4 es alquilo C1-6 o; como el resto de formula (2); W es -CH2 u O; y m es 0, 1 o 2 o una sal farmacéuticamente aceptable del mismo.
ARP100100118A 2009-01-20 2010-01-19 Pirazinonas sustituidas AR075032A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14579609P 2009-01-20 2009-01-20
US26260009P 2009-11-19 2009-11-19

Publications (1)

Publication Number Publication Date
AR075032A1 true AR075032A1 (es) 2011-03-02

Family

ID=42026372

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100118A AR075032A1 (es) 2009-01-20 2010-01-19 Pirazinonas sustituidas

Country Status (8)

Country Link
US (1) US8071606B2 (es)
EP (1) EP2389374A1 (es)
JP (1) JP2012515760A (es)
AR (1) AR075032A1 (es)
CA (1) CA2748587A1 (es)
TW (1) TW201028403A (es)
UY (1) UY32385A (es)
WO (1) WO2010084428A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008146A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
CN102216276A (zh) 2008-09-11 2011-10-12 辉瑞大药厂 取代的杂芳基物
JP5086480B2 (ja) * 2009-03-11 2012-11-28 ファイザー・インク グルコキナーゼ活性化剤として使用されるベンゾフラニル誘導体
CN109963834B (zh) 2016-11-18 2023-04-14 综合研究实验室瑞典股份公司 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399564A (en) 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
DE4434637A1 (de) 1994-09-28 1996-04-04 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
DE19603576A1 (de) 1996-02-01 1997-08-07 Bayer Ag Acylierte 4-Amino und 4-Hydrazinopyrimidine
EA006301B1 (ru) 1999-01-22 2005-10-27 Элан Фармасьютикалз, Инк. Ацильные производные, используемые для лечения опосредованных vla-4 расстройств
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
AU2002237664A1 (en) 2000-11-20 2002-05-27 Bristol-Myers Squibb Company Pyridone derivatives as AP2 inhibitors
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−iv阻害剤
EA200300944A1 (ru) 2001-02-28 2004-04-29 Мерк Энд Ко., Инк. Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
AP1822A (en) 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
WO2003092670A1 (en) 2002-05-03 2003-11-13 Warner-Lambert Company Llc Bombesin antagonists
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1433778A1 (en) 2002-12-23 2004-06-30 Jerini AG Use of nitriles as rotamase inhibitors
US7262196B2 (en) * 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ[e]アズレン誘導体及びそれらのアナログ
WO2006015159A2 (en) 2004-07-29 2006-02-09 Merck & Co., Inc. Potassium channel inhibitors
JP2008511659A (ja) 2004-09-01 2008-04-17 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4−ピリミジンジアミン化合物の合成
JP4167218B2 (ja) 2004-12-22 2008-10-15 株式会社メタル建材 薄板用タッピンねじ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
BRPI0615236A2 (pt) 2005-08-31 2011-05-10 Astellas Pharma Inc derivado de tiazol
JP2009013065A (ja) 2005-10-14 2009-01-22 Astellas Pharma Inc 縮合へテロ環化合物
EP1951680A4 (en) 2005-11-15 2011-08-10 Astrazeneca Ab NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE
JP5302012B2 (ja) * 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
WO2007117995A2 (en) 2006-03-30 2007-10-18 Takeda San Diego, Inc. Kinase inhibitors
WO2008079787A2 (en) * 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
MX2010007853A (es) 2008-01-18 2010-10-06 Astellas Pharma Inc Derivado de fenilacetamida.

Also Published As

Publication number Publication date
WO2010084428A1 (en) 2010-07-29
EP2389374A1 (en) 2011-11-30
CA2748587A1 (en) 2010-07-29
UY32385A (es) 2010-08-31
TW201028403A (en) 2010-08-01
US20100184777A1 (en) 2010-07-22
US8071606B2 (en) 2011-12-06
JP2012515760A (ja) 2012-07-12

Similar Documents

Publication Publication Date Title
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR085149A1 (es) Moduladores del receptor de glucagon
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR075635A1 (es) N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
BR112015021027A8 (pt) compostos terapêuticos, seus usos, e composições farmacêuticas
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
PE20211472A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
PE20141067A1 (es) Compuestos para el tratamiento de la adiccion
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
AR075951A1 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
PE20141556A1 (es) Derivados de etinilo como moduladores alostericos de mglur5
AR087274A1 (es) Derivados de amidas heterociclicas como antagonistas de receptores p2x7
AR080703A1 (es) Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal